Přihlásit se Zaregistrujte se zdarma

Návratnost jmění společnosti SinoMab BioScience

Jaká je hodnota metriky Návratnost jmění společnosti SinoMab BioScience?

Hodnota metriky Návratnost jmění společnosti SinoMab BioScience Limited je -69.74%

Jaká je definice metriky Návratnost jmění?



Návratnost kapitálu (Return on equity - ROE) je rentabilita vlastního kapitálu. Vypočítá se vydělením čistého příjmu za fiskální rok vlastním kapitálem.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Návratnost jmění společností v sektoru Health Care sektor na HKSE ve srovnání se společností SinoMab BioScience

Čemu se věnuje společnost SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Firmy s metrikou návratnost jmění podobnou společnosti SinoMab BioScience